Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds
详细信息 查看全文
- 作者：Gregory J. Crowther ; Alberto J. Napuli ; James H. Gilligan ; Kerstin Gagaring ; Rachel Borboa ; Carolyn Francek ; Zhong Chen ; Eleanor F. Dagostino ; Justin B. Stockmyer ; Yu Wang ; Philip P. Rodenbough ; Lisa
- 关键词：Target-based drug development ; Enzyme activity assays ; Antimalarial compounds
- 刊名：Molecular and Biochemical Parasitology
- 出版年：2011
- 出版时间：January 2011
- 年：2011
- 卷：175
- 期：1
- 页码：21-29
- 全文大小：514 K
文摘
The efficacy of most marketed antimalarial drugs has been compromised by evolution of parasite resistance, underscoring an urgent need to find new drugs with new mechanisms of action. We have taken a high-throughput approach toward identifying novel antimalarial chemical inhibitors of prioritized drug targets for Plasmodium falciparum, excluding targets which are inhibited by currently used drugs. A screen of commercially available libraries identified 5655 low molecular weight compounds that inhibit growth of P. falciparum cultures with EC50 values below 1.25 μM. These compounds were then tested in 384- or 1536-well biochemical assays for activity against nine Plasmodium enzymes: adenylosuccinate synthetase (AdSS), choline kinase (CK), deoxyuridine triphosphate nucleotidohydrolase (dUTPase), glutamate dehydrogenase (GDH), guanylate kinase (GK), N-myristoyltransferase (NMT), orotidine 5′-monophosphate decarboxylase (OMPDC), farnesyl pyrophosphate synthase (FPPS) and S-adenosylhomocysteine hydrolase (SAHH). These enzymes were selected using TDRtargets.org, and are believed to have excellent potential as drug targets based on criteria such as their likely essentiality, druggability, and amenability to high-throughput biochemical screening. Six of these targets were inhibited by one or more of the antimalarial scaffolds and may have potential use in drug development, further target validation studies and exploration of P. falciparum biochemistry and biology.